目的 建立分子信标实时PCR检测病理性瘢痕相关p53基因第72密码子单核苷酸多态性的新方法.方法 采集瘢痕疙瘩患者外周血28例,提取DNA并用分子信标PCR检测p53基因多态性.设计一对p53基因第72密码子单核苷酸多态性荧光分子信标探针,荧光定量PCR检测该位点单核苷酸(SNP),并与反向斑点杂交法,DNA直接测序等方法比较.结果 定量荧光PCR荧光分子信标检测的结果与测序结果吻合率达到100％,高于反向斑点杂交法且简便快捷.结论 分子信标实时PCR检测技术适合临床p53基因第72密码子单核苷酸多态性快速诊断.%Objective To investigate the effect of piperphentonamine hydrochloride (PPTA) on cognitive deficits induced by ischemia-reperfusion and explore the possible mechanisms. Methods SD rats were randomly divided into sham-operated group, ischemia-reperfusion group (with saline injection), PPTA-treated groups (2.5, 5,10 mg/kg) and edaravone-treated group (6 mg/kg). Cerebral ischemia-reperfusion injury was induced by middle cerebral artery occlusion, and the agents were administrated 1 h after ischemia. At 24 h after ischemia, step-through passive avoidance test was carried out, and 24 h later IL-1β, TNF-α, caspase-3 and HSP-70 mRNA expressions in the ischemic brain tissues were measured with RT-PCR. Results In the step-through passive avoidance test, the rats in the ischemia-reperfusion group showed significantly shorter latency and more error times than those in the sham group, and these behavioral changes were improved significantly by treatments with PPTA and edaravone. Cerebral ischemia-reperfusion caused significantly increased expressions of IL-lβ, TNF-α, caspase-3 and HSP-70 mRNA, and these changes were obviously reversed by PPTA, but not by edaravone. Conclusions PPTA can reverse cognitive deficits induced by cerebral ischemia-reperfusion probably by decreasing the inflammatory responses and cell apoptosis in the brain, suggesting its potential as a new therapeutic agent for improving the cognitive function following cerebral ischemia-reperfusion.
展开▼
